Which comes first: the antigen or the adjuvant?

Abstract

Recent attempts to develop an HIV-1 vaccine indicate that viral replication can be limited by the induction of viral-specific T cell responses; however, recent trials of vaccine candidates designed to target CD8⁺ T cell responses were unsuccessful. In this issue, Sui and colleagues used a nonhuman primate model to investigate the effect of various vaccine adjuvants on the efficacy of SIV immunization. Unexpectedly, Sui et al. discovered that animals given adjuvant alone in the absence of SIV antigen exhibited a pronounced decrease in viral load following viral challenge. Vaccination with viral antigens combined with adjuvant correlated with the expansion of a population of cells with similarity to myeloid-derived suppressor cells (MDSCs) that may have suppressed vaccine-elicited T cell responses. Together, these results suggest that both innate and adaptive vaccine-elicited immune responses will need to be considered in future HIV-1 vaccine development.

The HIV-1 vaccine field has debated the importance of eliciting strong functional antibody responses to prevent viral invasion of target cells versus eliciting potent T cell responses to kill virus-infected cells. This debate has converged on the consensus that both arms of the immune response will likely be necessary to achieve effective HIV-1 vaccination (1, 2). Additionally, the field has turned toward investigating TLR agonists and other adjuvants to enhance dendritic cell antigen presentation and augment vaccine-elicited responses (3–8). Despite repeated attempts to produce an efficacious HIV-1 vaccine, our knowledge of the adjuvant-specific impact on both the humoral and cellular arms of vaccine-elicited immune responses is still nascent. Moreover, the necessity of HIV-1 vaccine candidates to engage the innate immune system is an ongoing area of investigation (9, 10).

Vaccine adjuvant: an unexpected effect

In this issue, Sui et al. have demonstrated an unexpected effect of vaccine adjuvants on the development of T cell–mediated immunity that is potentially explained by innate immune regulation of vaccine-elicited cellular responses (11). While the investigated application of an adjuvanted peptide-prime/modified vaccinia Ankara (MVA) boost simian immunodeficiency virus (SIV) vaccine approach did not protect against SIV acquisition in the nonhuman primate rectal challenge model, there was a notable decrease in viral load at set point in animals that received the SIV vaccine in combination with an adjuvant that modulates the T cell coinhibitory molecule PD1. Surprisingly, animals that received adjuvant alone exhibited a more pronounced decrease in viral load at both peak and set-point viremia compared with that observed in animals receiving adjuvant in combination with vaccine antigen. This adjuvant-protective effect was especially pronounced in animals that expressed the protective MHC class I allele Mamu-A*01. Moreover, this observed virus control was abrogated by depletion of CD8⁺ T cells. Thus, Sui and colleagues hypothesized that innate regulatory mechanisms limit the MHC class I–restricted cytotoxic T cell responses elicited by the vaccine antigens delivered with adjuvant compared with responses seen with adjuvant alone. In fact, Sui et al. demonstrated a correlation between the set-point viral load and the peripheral expansion of a myeloid cell population that phenotypically resembled myeloid-derived suppressor cells (MDSCs), suggesting an innate dampening of the vaccine-elicited responses following viral challenge (11). This finding raises two important points to consider in future vaccine strategies for HIV-1 and other pathogens: (a) what is the impact of novel vaccine adjuvants on global immunity following vaccination, and (b) should vaccine strategies avoid stimulation of innate immune cell populations such as MDSCs that could dampen vaccine-elicited immune responses?

The results from the study by Sui and colleagues (11) extend previous observations that TLR ligands may expand MDSCs in vivo (12–16). Additionally, the results from Sui et al. (11) emphasize that adjuvant-driven MDSC expansion may have a detrimental impact on vaccine-induced immune responses and highlight the need for additional investigation on the impact of vaccine adjuvants on both innate and adaptive immune responses, including regulatory responses. The impact of the route of immunization on vaccine/adjuvant-induced MDSCs will also require further evaluation. Sui et al. used a mucosal route of immunization; however, it remains to be determined whether vaccine/adjuvant-induced MDSC responses are influenced by the route of immunization.

Future considerations for HIV-1 vaccine development

The work by Sui et al. (11) has highlighted innate immune cell regulation as a potential mechanism explaining the lack of success of clinical trials that aimed to elicit CD8⁺ T cell responses that would reduce or eliminate virus replication, such as the STEP trial, which evaluated the efficacy of an adenovirus-based vaccine candidate.(17). While more studies will be required to confirm the impact of MDSCs on vaccine-elicited cellular immune responses, the data put forth by Sui et al. (11) suggest that assessing the myeloid cell expansion in response to vaccination could be critical in improving effective CD8⁺ T cell responses elicited by HIV-1 vaccination. As current HIV-1 vaccine candidates, such as the cytomegalovirus-vectored vaccines (18), that target T cell responses and the elimination of early viral reservoirs move forward in preclinical and clinical vaccine trials, the impact of innate regulation on vaccine-elicited T cell responses should be considered in attempts to improve the effectiveness of these HIV-1 vaccines. Development of vaccines that target both cellular and humoral immune responses to block HIV-1 infection and eliminate early viral reservoirs will require researchers in the HIV-1 vaccine field to consider the complex immunologic principles that regulate the T and B cell responses that effective vaccines seek to generate.

Footnotes

Conflict of interest: The authors have declared that no conflict of interest exists.

Reference information: J Clin Invest. 2014;124(6):2364–2365. doi:10.1172/JCI76263.

See the related article at Vaccine-induced myeloid cell population dampens protective immunity to SIV.

References

1. Excler JL, Robb ML, Kim JH. HIV-1 vaccines: challenges and new perspectives. Hum Vaccin Immunother. doi:10.4161/hv.28462.
   View this article via: PubMed Google Scholar
2. Haynes BF, McElrath MJ. Progress in HIV-1 vaccine development. Curr Opin HIV AIDS. 2013;8(4):326–332.
3. Moody MA, et al. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J Virol. 2014;88(6):3329–3339.
   View this article via: PubMed CrossRef Google Scholar
4. Buffa V, Klein K, Fischetti L, Shattock RJ. Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice. PLoS One. 2012;7(12):e50529.
   View this article via: PubMed CrossRef Google Scholar
5. Fouda GG, et al. Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk. J Virol. 2013;87(12):6986–6999.
   View this article via: PubMed CrossRef Google Scholar
6. Staats HF, et al. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J Immunol. 2001;167(9):5386–5394.
   View this article via: PubMed CrossRef Google Scholar
7. Bradney CP, Sempowski GD, Liao HX, Haynes BF, Staats HF. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol. 2002;76(2):517–524.
   View this article via: PubMed CrossRef Google Scholar
8. Egan MA, et al. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine. 2004;22(27–28):3774–3788.
   View this article via: PubMed Google Scholar
9. Ackerman ME, Dugast AS, Alter G. Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Annu Rev Med. 2012;63:113–130.
   View this article via: PubMed CrossRef Google Scholar
10. Altfeld M, Fadda L, Frleta D, Bhardwaj N. DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol. 2011;11(3):176–186.
    View this article via: PubMed CrossRef Google Scholar
11. Sui Y, et al. Vaccine-induced myeloid cell population dampens protective immunity to SIV. J Clin Invest. 2014;124(6):2538–2549.
    View this article via: JCI Google Scholar
12. Ray A, Chakraborty K, Ray P. Immunosuppressive MDSCs induced by TLR signaling during infection and role in resolution of inflammation. Front Cell Infect Microbiol. 2013;3:52.
    View this article via: PubMed Google Scholar
13. Dang Y, et al. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin Cancer Res. 2012;18(11):3122–3131.
    View this article via: PubMed CrossRef Google Scholar
14. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol. 2009;85(6):996–1004.
    View this article via: PubMed CrossRef Google Scholar
15. Rieber N, et al. Flagellin induces myeloid-derived suppressor cells: implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease. J Immunol. 2013;190(3):1276–1284.
    View this article via: PubMed CrossRef Google Scholar
16. Garg A, Spector SA. HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. J Infect Dis. 2014;209(3):441–451.
    View this article via: PubMed CrossRef Google Scholar
17. Buchbinder SP, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–1893.
    View this article via: PubMed CrossRef Google Scholar
18. Hansen SG, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011;473(7348):523–527.
    View this article via: PubMed CrossRef Google Scholar